Special Issue

Targeted Therapy for Breast Cancer: Focus on the Apoptosis Pathway

Message from the Guest Editors

Apoptosis is a type of programmed cell death. There are two major types of apoptosis pathway: 1) intrinsic pathways that are initiated by intracellular pathways such as DNA damage, ER stress, hypoxia, and metabolic stress, and 2) extrinsic pathways that are initiated by death receptor activation (TRAILR and FAS) from a signal outside cells. Apoptosis resistance is a hallmark of human cancer, and apoptosis regulators have been targeted for drug development regarding cancer treatment. Breast cancer is a heterogeneous disease that often develops resistance toward standard care treatments, such as hormone therapy, anti-HER2 therapy, chemotherapy, or radiotherapy. It has been reported that anti-apoptotic BCL-2 family members are frequently found to be up-regulated in breast cancer and correlate with poor prognosis. In this issue, we welcome original research and review articles that discuss the discovery of novel mechanisms of apoptosis, potential drug targets, biomarkers, and new inhibitors that may overcome apoptosis resistance and provide effective therapeutic approaches for use in the treatment of breast cancer.

Guest Editors

Dr. Jangsoon Lee

Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Dr. Bora Lim

Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA

Deadline for manuscript submissions

closed (30 April 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/102378

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).